Stockreport

Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints

Athenex, Inc.  (ATNX) 
Last athenex, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.athenex.com
PDF BUFFALO, N.Y., July 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercial [Read more]